Advisory Alpha LLC Makes New Investment in DexCom, Inc. (NASDAQ:DXCM)

Advisory Alpha LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,642 shares of the medical device company’s stock, valued at approximately $205,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Versant Capital Management Inc acquired a new position in DexCom during the 4th quarter worth approximately $25,000. Riverview Trust Co increased its holdings in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in shares of DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after acquiring an additional 265 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new position in shares of DexCom during the third quarter worth approximately $57,000. Finally, Covestor Ltd lifted its holdings in shares of DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.30% of the stock is owned by corporate insiders.

DexCom Price Performance

NASDAQ DXCM opened at $88.75 on Friday. The company has a 50-day moving average price of $79.25 and a 200-day moving average price of $77.51. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $34.67 billion, a P/E ratio of 53.14, a PEG ratio of 2.23 and a beta of 1.12. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

Analyst Ratings Changes

DXCM has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Wells Fargo & Company boosted their price objective on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Sanford C. Bernstein raised their target price on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Oppenheimer dropped their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.29.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.